Showing results (821-830 of 1,396) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|June 1, 2018
Landscape of Microsatellite Instability Across 39 Cancer TypesRussell Bonneville, Melanie A Krook, Esko A Kautto, et al.
JCO Precision Oncology|June 24, 2021
Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic EvaluationVeda N Giri, Elias Obeid, Laura Gross, et al.
JCO Precision Oncology|May 11, 2022
Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy ResponseKristen Bibeau, Luis Féliz, Christine F Lihou, et al.
JCO Precision Oncology|May 11, 2022
Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based TherapyGiovanni Randon, Giulia Maddalena, Marco Maria Germani, et al.
JCO Precision Oncology|June 6, 2022
Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based ChemotherapyPedro Luiz Serrano Uson Junior, Umair Majeed, Jun Yin, et al.
JCO Precision Oncology|June 8, 2022
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune SignaturesKabir Mody, Prerna Jain, Sherif M El-Refai, et al.
JCO Precision Oncology|June 23, 2022
RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal AdenocarcinomaFanfan Xie, Ding Ding, Cong Lin, et al.
JCO Precision Oncology|June 7, 2021
Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology PracticeJ Kevin Hicks, Rachel Howard, Phillip Reisman, et al.
JCO Precision Oncology|July 12, 2021
Prevalence and Characterization of Biallelic and Monoallelic NTHL1 and MSH3 Variant Carriers From a Pan-Cancer Patient PopulationErin E Salo-Mullen, Anna Maio, Semanti Mukherjee, et al.
JCO Precision Oncology|July 12, 2021
Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase InhibitorJia Luo, Alex Makhnin, Yosef Tobi, et al.
Pageof 140